*Pseudomonas aeruginosa* is an important pathogen that is the main cause of acute nosocomial infections, especially in immunocompromised patients [@bib1]. The resistance of *P. aeruginosa* to carbapenem is becoming a major global threat and is exacerbated by the excessive use of carbapenem [@bib2], [@bib3]. This resistance is mainly due to the alteration or loss of the outer membrane porin protein (*oprD*), to the increased expression of the efflux pumps and the production of carbapenemase, mainly Verona integron-encoded metallo-β-lactamase (VIM) and imipenem (IMP) [@bib2], [@bib3].

In this study, we report the emergence of carbapenem-resistant *P. aeruginosa* isolated from rectal swabs of 23 intensive care unit patients treated with carbapenem for more than 1 week between October 2016 and February 2017 from Saint-George Hospital in Lebanon. Carbapenem-resistant organisms were screened using agar plates with Ertapenem (2 μg/mL). Four carbapenem-resistant *P. aeruginosa* were isolated and identified by MALDI-TOF MS. Antimicrobial susceptibility testing was performed on Müller-Hinton agar using the disc diffusion method, and Etest was performed to determine the MIC of IMP, as recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (<https://www.sfm-microbiologie.org/wp-content/uploads/2019/01/CASFM2019_V1.0.pdf>). The phenotypic detection of carbapenemase was confirmed using the Carba NP test [@bib4]. The carbapenemase encoding genes were screened by real-time PCR and standard PCR, and were then sequenced. Molecular characterization of the *oprD* gene was performed using PCR amplification and sequencing [@bib5]. Analysis of the sequenced *oprD* gene was compared against the reference strain *P. aeruginosa* PA01 using Multalin alignment software (<http://multalin.toulouse.inra.fr/multalin/>). Multilocus sequence typing (MLST) was performed to determine the genetic relationship among the clinical isolate as described on the Institute Pasteur\'s MLST website (<https://pubmlst.org/paeruginosa/>).

The results indicated that *P. aeruginosa* isolates were resistant to all antibiotics tested except to colistin and fosfomycin, with MICs for IMP \>32 μg/mL. All isolates harboured the *bla*~VIM-2~ gene, except *P. aeruginosa* (PA-4) ([Table 1](#tbl1){ref-type="table"}). In addition, all isolates had mutations in the *oprD* gene ([Fig. 1](#fig1){ref-type="fig"}). MLST analysis revealed that three *P. aeruginosa* (PA-3, PA-6, PA-16), and one *P. aeruginosa* (PA-4) isolates harboured sequence types (ST) 357 and ST233 respectively ([Table 1](#tbl1){ref-type="table"}). Conjugal transfer between carbapenemase-producing *P. aeruginosa* and *Escherichia coli* (J35) succeeded, to yield *E. coli* transconjugants harbouring a ∼45 kb plasmid, except for the clone ST233, suggesting that these metallo-β-lactamase *bla*~VIM-2~ were plasmid encoded for ST357 and chromosomally encoded for ST233.Table 1Phenotypic and genotypic features of carbapenem-resistant clinical isolatesTable 1*Pseudomonas aeruginosa* strainSourceAntibiotic resistance profileIMP MIC (μg/mL)Carba NP testVIM-2STPA-3Rectal swabTIC, TCC, TZP, CAZ, FEP, IMP, ERT, AK, TOB, CIP, F, DO, SXT, R\>32++357PA-16Rectal swabTIC, TCC, TZP, CAZ, FEP, IMP, ERT, AK, TOB, CIP, F, DO, SXT, R\>32++357PA-6Rectal swabTIC, TCC, TZP, CAZ, FEP, IMP, ERT, AK, TOB, CIP, F, DO, SXT, R\>32++357PA-4Rectal swabTIC, TCC, TZP, CAZ, FEP, IMP, ERT, AK, TOB, CIP, F, DO, SXT,R\>32+−233[^1]Fig. 1Genetic representation of *oprD* gene. (a) Nucleotide alignment of *oprD* gene and (b) protein alignment of *oprD* gene. For *Pseudomonas aeruginosa* PA-3, PA-16 and PA-6, large deletion of ten nucleotides from position 209 to 218 led to premature stop codon TGA in *oprD,* resulting in truncated polypeptide made of 90 aa residues. For *P. aeruginosa* PA-4, C to T substitution in nucleotide position 88 led to premature stop codon TAG in *oprD,* resulting in truncated polypeptide made of 29 aa residues.Fig. 1

Here we describe the emergence of carbapenem-resistant *P. aeruginosa* in Saint-Georges Hospital due to the presence of *bla*~VIM-2~ gene and mutations of the *oprD* gene. These results are in concordance with those previously reported in Lebanon, where Al Bayssari et al. [@bib3], [@bib6] have reported the emergence of VIM-2--producing *P. aeruginosa* in humans and animals. Other studies have also shown the spread of VIM-2--producing *P. aeruginosa* in different Lebanese hospitals [@bib7], [@bib8]. In addition, Christophy et al. [@bib9] revealed the presence of the *bla*~VIM~ gene in *P. stutzeri* collected from cancer patients in North Lebanon*.* However, none of those studies has revealed a plasmidic location of the *bla*~VIM-2~ gene. Our study also demonstrated that mutations leading to premature stop codon resulting in a defective protein *oprD* were the main cause of *P. aeruginosa*\'s resistance to carbapenem, as described above [@bib3], [@bib10]. The main finding in our study was the emergence of *P. aeruginosa* harbouring the VIM-2 plasmid, which has never been detected before in Lebanon, where all detected isolates had the chromosomic *bla*~VIM-2~ gene, or the studies did not specify the genetic location of the *bla*~VIM~ gene [@bib3]. MLST analysis showed that the three *P. aeruginosa* isolates harbouring the plasmid-encoded *bla*~VIM-2~ gene belonged to the ST357 clone, which has been found in different countries of central Europe [@bib11]. However, *P. aeruginosa* ST233, which has the chromosomic *bla*~VIM-2~ gene, has already been described in Lebanon as well as in various countries in the Mediterranean basin [@bib3], [@bib12].

To conclude, our study is the first to report the detection of the plasmid-encoded *bla*~VIM-2~ gene in Lebanon. This finding poses a serious public health problem because the plasmid containing this β-lactamase is a major source of dissemination of this enzyme. An urgent strategy must be implemented to control the spread of these resistant microorganisms in hospitalized patients.
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[^1]: AK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; DO, doxycycline; ERT, ertapenem; F, nitrofurantoin; FEP, cefepime; FF, fosfomycin; IPM, imipenem; R, rifampicin; ST, sequence, type; SXT, trimethoprim/sulfamethoxazole; TCC, ticarcillin/clavulanic, acid; TIC, ticarcillin; TOB, tobramycin; TZP, piperacillin/tazobactam.
